News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Apr 06, 2022, 08:00 ET FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...

Mar 23, 2022, 20:27 ET Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...

Dec 22, 2021, 18:53 ET Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis

Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx®...

Dec 22, 2021, 16:23 ET La FDA aprueba Leqvio® (inclisiran) de Novartis, el primer ARNip de su clase para reducir el colesterol y mantenerlo bajo con dos dosis al año

Dec 22, 2021, 16:23 ET FDA 批准Novartis 的 Leqvio® (inclisiran)，这是一种可降胆固醇且每年两剂即可维持效果的首创 siRNA

Dec 22, 2021, 16:23 ET FDA核准Novartis Leqvio® (inclisiran)，這是一種可降膽固醇且每年兩劑即可維持效果的首創 siRNA

Dec 22, 2021, 16:22 ET FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) ...

Dec 10, 2021, 08:02 ET Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...

Dec 08, 2021, 09:32 ET New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy...

Nov 04, 2021, 13:57 ET Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)

Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor – in...

Sep 16, 2021, 18:10 ET Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an...

Aug 31, 2021, 08:24 ET Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis today announced the launch of "Meet The PROS," an initiative to raise awareness and offer new educational resources for PIK3CA-Related...

Jun 04, 2021, 09:08 ET Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor...

Jun 03, 2021, 17:06 ET Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu)...

Jun 03, 2021, 12:24 ET Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of...

Jun 02, 2021, 09:10 ET Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in postmenopausal...

Jun 01, 2021, 16:42 ET Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx®...

May 28, 2021, 16:49 ET Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018, assessing the ...

May 26, 2021, 08:00 ET Novartis commits to addressing racial disparities in breast cancer screening, treatment and care

Novartis today announced the launch of More Than Just Words, a multiyear commitment to promote health equity in breast cancer care, where there is...

May 19, 2021, 17:15 ET Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the...

Apr 12, 2021, 13:20 ET Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair®...

Feb 16, 2021, 16:31 ET Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto®...

Dec 15, 2020, 19:31 ET Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF

Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that...

Dec 09, 2020, 09:10 ET Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer

Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with endocrine therapy, marking the...

Dec 07, 2020, 08:30 ET Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine

Novartis today announced a partnership with Karamo Brown, Emmy-nominated host from Netflix's hit show "Queer Eye," to support and empower people...